Yu-Qing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu-Qing Wang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Biao Luo
Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China
1 shared publication- Gao-Jun Teng
Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China
1 shared publication - Hai-Dong Zhu
Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China
1 shared publication - Jianjian Chen
Department of Radiology, Center of Interventional Radiology and Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China
1 shared publication - Rui Li
Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China
1 shared publication - Zhi-Cheng Jin
Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 25 July 2023
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 12 (1) , 15-24
New First-line Immunotherapy-based Therapies for Unresectable Hepatocellular Carcinoma: A Living Network Meta-analysis
Several first-line immune checkpoint inhibitor (ICI)-based combination therapies have been identified for unresectable hepatocellular carcinoma (uHCC). This network meta-analysis (NMA) aimed to provide the most updated evidence about the preferred first-line ICI-based regimens for uHCC.
- 25 July 2023
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 12 (1) , 15-24
Open AccessNew First-line Immunotherapy-based Therapies for Unresectable Hepatocellular Carcinoma: A Living Network Meta-analysis
Several first-line immune checkpoint inhibitor (ICI)-based combination therapies have been identified for unresectable hepatocellular carcinoma (uHCC). This network meta-analysis (NMA) aimed to provide the most updated evidence about the preferred first-line ICI-based regimens for uHCC.